A sector worth backing: Stuart Rose on resilience, research strength, and investor confidence
Season 1, Episode 3
In this interview, Stuart Rose offers a broader market view of the UK life sciences ecosystem, combining scientific, commercial, and sector leadership perspectives.
He argues that the UK continues to benefit from extraordinary underlying strengths: globally respected universities, high-quality scientific talent, a collaborative culture, and a proven ability to innovate under pressure.
He is equally candid, however, about the constraints facing smaller and emerging companies. The funding environment has been difficult, investor caution has increased, and many businesses need more practical support to secure investment and move forwards with confidence. Even so, his outlook remains strongly positive: the sector has depth, resilience, and long-term strategic importance, provided the right mechanisms are in place to keep capital and capability flowing into early-stage innovation.